Bayesian regression models for cost-effectiveness analysis
AbstractNo abstract is available for this item.
Download InfoIf you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
Bibliographic InfoArticle provided by Springer in its journal The European Journal of Health Economics.
Volume (Year): 6 (2005)
Issue (Month): 1 (March)
Contact details of provider:
Web page: http://link.springer.de/link/service/journals/10198/index.htm
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Karl Claxton, 1999. "Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 269-274.
- William E. Griffiths & R. Carter Hill & Christopher J. O'Donnell, 2001. "Including Prior Information in Probit Model Estimation," Department of Economics - Working Papers Series 816, The University of Melbourne.
- Andrew R. Willan & Bernie J. O'Brien, 2001. "Cost prediction models for the comparison of two groups," Health Economics, John Wiley & Sons, Ltd., vol. 10(4), pages 363-366.
- Anthony O'Hagan & John W. Stevens, 2001. "A framework for cost-effectiveness analysis from clinical trial data," Health Economics, John Wiley & Sons, Ltd., vol. 10(4), pages 303-315.
- Andrew H. Briggs, 1999. "A Bayesian approach to stochastic cost-effectiveness analysis," Health Economics, John Wiley & Sons, Ltd., vol. 8(3), pages 257-261.
- Christian Kronborg Andersen & Kjeld Andersen & Per Kragh-S�rensen, 2000. "Cost function estimation: the choice of a model to apply to dementia," Health Economics, John Wiley & Sons, Ltd., vol. 9(5), pages 397-409.
- Andrew R. Willan & Andrew H. Briggs & Jeffrey S. Hoch, 2004. "Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data," Health Economics, John Wiley & Sons, Ltd., vol. 13(5), pages 461-475.
- Elisabeth Fenwick & Karl Claxton & Mark Sculpher, 2001. "Representing uncertainty: the role of cost-effectiveness acceptability curves," Health Economics, John Wiley & Sons, Ltd., vol. 10(8), pages 779-787.
- E. Kathleen Adams & Vincent P. Miller & Carla Ernst & Brenda K. Nishimura & Cathy Melvin & Robert Merritt, 2002. "Neonatal health care costs related to smoking during pregnancy," Health Economics, John Wiley & Sons, Ltd., vol. 11(3), pages 193-206.
- Karl Claxton & Larry F. Lacey & Stephen G. Walker, 2000. "Selecting treatments: a decision theoretic approach," Journal of the Royal Statistical Society Series A, Royal Statistical Society, vol. 163(2), pages 211-225.
- Negrin, Miguel A. & Vázquez-Polo, Francisco-José, 2008. "Incorporating model uncertainty in cost-effectiveness analysis: A Bayesian model averaging approach," Journal of Health Economics, Elsevier, vol. 27(5), pages 1250-1259, September.
- Moreno, E. & Girón, F.J. & Martínez, M.L. & Vázquez-Polo, F.J. & Negrín, M.A., 2013. "Optimal treatments in cost-effectiveness analysis in the presence of covariates: Improving patient subgroup definition," European Journal of Operational Research, Elsevier, vol. 226(1), pages 173-182.
- Moreno, Elías & Girón, F.J. & Vázquez-Polo, F.J. & Negrín, M.A., 2012. "Optimal healthcare decisions: The importance of the covariates in cost–effectiveness analysis," European Journal of Operational Research, Elsevier, vol. 218(2), pages 512-522.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Guenther Eichhorn) or (Christopher F Baum).
If references are entirely missing, you can add them using this form.